Do analysts rate ENLV or DTSQ?

Enlivex Therapeutics presently has a consensus price target of $247.50, indicating a potential upside of 18,233.33%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Enlivex Therapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, ENLV or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is ENLV or DTSQ more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat DT Cloud Star Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% DT Cloud Star Acquisition N/A N/A N/A

Does the media prefer ENLV or DTSQ?

In the previous week, Enlivex Therapeutics had 1 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Enlivex Therapeutics' score of 0.88 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ENLV or KLRS?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is ENLV or KLRS more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Kalaris Therapeutics N/A -71.71% -42.95%

Does the media refer more to ENLV or ATRA?

In the previous week, Atara Biotherapeutics had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 4 mentions for Enlivex Therapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Enlivex Therapeutics' score of 0.88 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ENLV or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is ENLV or ACRV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Acrivon Therapeutics N/A -70.14% -61.60%

Does the media refer more to ENLV or ACRV?

In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 4 articles in the media. Acrivon Therapeutics' average media sentiment score of 1.14 beat Enlivex Therapeutics' score of 0.88 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acrivon Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enlivex Therapeutics (ENLV) Competitors

$1.35 -0.13 (-8.47%)

As of 08/28/2026 04:00 PM Eastern

Compare

ENLV vs. YARW, DTSQ, KLRS, ATRA, and ACRV

Should you buy Enlivex Therapeutics stock or one of its competitors? Enlivex Therapeutics's main competitors and comparable companies include Yarrow Bioscience (YARW), DT Cloud Star Acquisition (DTSQ), Kalaris Therapeutics (KLRS), Atara Biotherapeutics (ATRA), and Acrivon Therapeutics (ACRV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Enlivex Therapeutics compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Enlivex Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Enlivex Therapeutics' return on equity of 248.08% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Enlivex Therapeutics	N/A	248.08%	206.39%

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enlivex Therapeutics has lower revenue, but higher earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	173.32	-$26.48M	-$14.64	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

In the previous week, Enlivex Therapeutics had 2 more articles in the media than Yarrow Bioscience. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 2 mentions for Yarrow Bioscience. Enlivex Therapeutics' average media sentiment score of 0.88 beat Yarrow Bioscience's score of 0.30 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Yarrow Bioscience	Neutral
Enlivex Therapeutics	Positive

Yarrow Bioscience currently has a consensus target price of $58.00, suggesting a potential upside of 56.76%. Enlivex Therapeutics has a consensus target price of $247.50, suggesting a potential upside of 18,233.33%. Given Enlivex Therapeutics' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Yarrow Bioscience has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Yarrow Bioscience on 11 of the 16 factors compared between the two stocks.

How does Enlivex Therapeutics compare to DT Cloud Star Acquisition?

Enlivex Therapeutics (NASDAQ:ENLV) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Enlivex Therapeutics presently has a consensus price target of $247.50, indicating a potential upside of 18,233.33%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Enlivex Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Enlivex Therapeutics had 1 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Enlivex Therapeutics' score of 0.88 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Enlivex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Enlivex Therapeutics' return on equity of 248.08% beat DT Cloud Star Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
DT Cloud Star Acquisition	N/A	N/A	N/A

Summary

Enlivex Therapeutics beats DT Cloud Star Acquisition on 9 of the 11 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Kalaris Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enlivex Therapeutics' return on equity of 248.08% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

In the previous week, Enlivex Therapeutics had 3 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.87 beat Enlivex Therapeutics' score of 0.88 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Positive
Kalaris Therapeutics	Very Positive

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Enlivex Therapeutics currently has a consensus price target of $247.50, indicating a potential upside of 18,233.33%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 365.26%. Given Enlivex Therapeutics' higher possible upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Enlivex Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Summary

Enlivex Therapeutics beats Kalaris Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Atara Biotherapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enlivex Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Enlivex Therapeutics' return on equity of 248.08% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

In the previous week, Atara Biotherapeutics had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 4 mentions for Enlivex Therapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Enlivex Therapeutics' score of 0.88 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Enlivex Therapeutics presently has a consensus target price of $247.50, suggesting a potential upside of 18,233.33%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 3.26%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Enlivex Therapeutics has higher earnings, but lower revenue than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Atara Biotherapeutics	$120.77M	0.76	$32.69M	-$1.18	N/A

Summary

Enlivex Therapeutics beats Atara Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Acrivon Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Enlivex Therapeutics currently has a consensus price target of $247.50, indicating a potential upside of 18,233.33%. Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 555.34%. Given Enlivex Therapeutics' higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 4 articles in the media. Acrivon Therapeutics' average media sentiment score of 1.14 beat Enlivex Therapeutics' score of 0.88 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics' return on equity of 248.08% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Enlivex Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Enlivex Therapeutics beats Acrivon Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENLV vs. The Competition

Export

Metric	Enlivex Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.61M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.16	11.62	273.16	25.45
Price / Sales	N/A	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	0.01	16.53	12.98	6.14
Net Income	$1.24B	-$22.80M	$3.48B	$348.86M
7 Day Performance	-8.16%	-0.31%	0.13%	-0.80%
1 Month Performance	-30.77%	9.80%	7.08%	4.13%
1 Year Performance	-91.43%	55.66%	24.67%	15.17%

Enlivex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENLV Enlivex Therapeutics	3.8597 of 5 stars	$1.35 -8.5%	$247.50 +18,233.3%	-91.4%	$23.61M	N/A	N/A	70	News Coverage Positive News Upcoming Earnings Analyst Upgrade Short Interest Decrease
YARW Yarrow Bioscience	2.1969 of 5 stars	$39.25 -0.6%	$58.00 +47.8%	N/A	$105.46M	$570K	N/A	30	Short Interest Increase
DTSQ DT Cloud Star Acquisition	1.8846 of 5 stars	$11.36 +0.2%	N/A	+8.5%	$100.85M	N/A	N/A	N/A	Positive News Short Interest Decrease
KLRS Kalaris Therapeutics	2.4957 of 5 stars	$4.20 +2.4%	$18.75 +346.4%	-1.2%	$97.60M	N/A	N/A	110
ATRA Atara Biotherapeutics	1.6523 of 5 stars	$9.84 +4.0%	$9.50 -3.5%	-23.7%	$94.96M	$120.77M	N/A	330	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. YARW, DTSQ, KLRS, ATRA, and ACRV

How does Enlivex Therapeutics compare to Yarrow Bioscience?

Summary

How does Enlivex Therapeutics compare to DT Cloud Star Acquisition?

Summary

How does Enlivex Therapeutics compare to Kalaris Therapeutics?

Summary

How does Enlivex Therapeutics compare to Atara Biotherapeutics?

Summary

How does Enlivex Therapeutics compare to Acrivon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. YARW, DTSQ, KLRS, ATRA, and ACRV

How does Enlivex Therapeutics compare to Yarrow Bioscience?

Is YARW or ENLV more profitable?

Do insiders and institutionals have more ownership in YARW or ENLV?

Which has better earnings and valuation, YARW or ENLV?

Does the media favor YARW or ENLV?

Do analysts recommend YARW or ENLV?

Which has more volatility and risk, YARW or ENLV?

Summary

How does Enlivex Therapeutics compare to DT Cloud Star Acquisition?

Do analysts rate ENLV or DTSQ?

Does the media prefer ENLV or DTSQ?

Do institutionals & insiders have more ownership in ENLV or DTSQ?

Which has higher valuation & earnings, ENLV or DTSQ?

Which has more volatility and risk, ENLV or DTSQ?

Is ENLV or DTSQ more profitable?

Summary

How does Enlivex Therapeutics compare to Kalaris Therapeutics?

Do institutionals and insiders believe in ENLV or KLRS?

Is ENLV or KLRS more profitable?

Does the media refer more to ENLV or KLRS?

Which has better valuation & earnings, ENLV or KLRS?

Do analysts rate ENLV or KLRS?

Which has more risk & volatility, ENLV or KLRS?

Summary

How does Enlivex Therapeutics compare to Atara Biotherapeutics?

Do institutionals and insiders have more ownership in ENLV or ATRA?

Is ENLV or ATRA more profitable?

Does the media refer more to ENLV or ATRA?

Which has more volatility and risk, ENLV or ATRA?

Do analysts recommend ENLV or ATRA?

Which has stronger earnings & valuation, ENLV or ATRA?

Summary

How does Enlivex Therapeutics compare to Acrivon Therapeutics?

Do analysts recommend ENLV or ACRV?

Does the media refer more to ENLV or ACRV?

Is ENLV or ACRV more profitable?

Which has more volatility & risk, ENLV or ACRV?

Which has higher valuation and earnings, ENLV or ACRV?

Do institutionals & insiders believe in ENLV or ACRV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools